Want to see AU:PIQ full AI Analyst Report?
Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.15
▼(-9.38% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance (sharp 2026 revenue drop, widening losses, and persistent cash burn) with only partial support from low balance-sheet leverage. Technicals remain soft (below key moving averages and negative MACD), and valuation is constrained by a loss-making profile (negative P/E) with no dividend support.
Positive Factors
Low financial leverage
Very low leverage reduces fixed financial obligations and preserves balance-sheet flexibility compared with a heavily debt-funded business. This gives Proteomics International more room to allocate capital toward diagnostic development and laboratory operations while limiting the direct impact of interest and refinancing pressure.
Negative Factors
Sharp revenue contraction
The sharp 2026 revenue decline interrupts the earlier modest growth trend and raises concern about the durability of customer demand or commercialization progress. Lower revenue reduces operating leverage, limits reinvestment capacity, and makes a near-term path to sustainable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low leverage reduces fixed financial obligations and preserves balance-sheet flexibility compared with a heavily debt-funded business. This gives Proteomics International more room to allocate capital toward diagnostic development and laboratory operations while limiting the direct impact of interest and refinancing pressure.
Read all positive factors
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.81M
Dividend YieldN/A
Average Volume (3M)105.74K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth-23.71%
EPS Growth-16.02%
CountryAU
Employees161
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,373,120
10 Day Avg. Volume56,474
30 Day Avg. Volume105,736
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.26
Price to Sales (P/S)67.98
P/FCF Ratio-2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$5.90M
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Company Description
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to pred...
How the Company Makes Money
null...
Proteomics International Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 480.45K | 278.01K | 960.39K | 892.14K | 730.34K | 1.49M |
| Gross Profit | -9.26M | -9.07M | 960.39K | -1.12M | -1.62M | -568.62K |
| EBITDA | -11.94M | -11.08M | -10.00M | -8.40M | -7.55M | -4.56M |
| Net Income | -9.66M | -8.56M | -8.11M | -6.38M | -6.23M | -4.97M |
Balance Sheet | ||||||
| Total Assets | 11.30M | 8.88M | 14.78M | 10.88M | 10.08M | 5.40M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 3.50M | 11.04M | 6.64M | 6.03M | 2.11M |
| Total Debt | 681.45K | 331.13K | 277.74K | 316.39K | 64.09K | 0.00 |
| Total Liabilities | 4.09M | 3.33M | 1.81M | 1.63M | 1.75M | 2.00M |
| Stockholders Equity | 7.45M | 5.81M | 13.17M | 9.41M | 8.38M | 3.39M |
Cash Flow | ||||||
| Free Cash Flow | -8.41M | -7.88M | -6.63M | -6.00M | -6.91M | -3.67M |
| Operating Cash Flow | -6.35M | -5.87M | -6.60M | -5.59M | -5.69M | -3.54M |
| Investing Cash Flow | -2.07M | -2.01M | -29.65K | -388.02K | -1.17M | -129.46K |
| Financing Cash Flow | 10.76M | 345.13K | 11.03M | 6.59M | 10.77M | 176.10K |
Proteomics International Laboratories Ltd. Technical Analysis
Negative
0.16
Price Trends
0.16
Negative
0.16
Negative
0.30
Negative
Market Momentum
>-0.01
Positive
45.00
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.16, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.
Proteomics International Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$5.60B | 119.18 | 7.11% | ― | 26.66% | 179.32% | |
54 Neutral | AU$11.50M | 6.42 | 206.11% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$850.63M | -7.86 | -51.15% | ― | ― | -44.83% | |
44 Neutral | AU$68.46M | -17.50 | -71.28% | ― | -51.74% | 32.00% | |
43 Neutral | AU$24.81M | -2.23 | -93.66% | ― | -23.71% | -16.02% | |
42 Neutral | AU$39.04M | -0.58 | -144.24% | ― | -23.82% | 12.36% |
* Healthcare Sector Average
AU:PIQ
Proteomics International Laboratories Ltd.
0.15
-0.17
-53.13%
AU:TLX
Telix Pharmaceuticals
16.47
2.87
21.10%
AU:VBS
Vectus Biosystems Limited
0.19
0.11
153.42%
AU:ADO
AnteoTech Ltd
0.02
>-0.01
-8.70%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.28
-0.87
-27.62%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-65.52%
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Lifts Revenue but Posts Wider Annual Loss
Aug 31, 2026
Proteomics International Laboratories Ltd reported a 3.0% increase in revenues from ordinary activities and other income to $3.61 million for the year ended 30 June 2026, but the company’s net loss widened 5.5% to $8.56 million. No dividends...
Proteomics International Outlines 2026 Governance Compliance and Board Structure
Aug 31, 2026
Proteomics International Laboratories Ltd has released its Corporate Governance Statement for the financial year ended 30 June 2026, outlining compliance with the ASX Corporate Governance Council’s fourth edition principles and recommendatio...
Proteomics International Wins Australian Patent for Endometriosis Blood Test
Aug 13, 2026
Proteomics International has received a notice of acceptance from IP Australia for a patent covering its PromarkerEndo blood test, an innovative diagnostic for endometriosis that uses specific protein biomarkers to aid diagnosis and guide treatmen...
Proteomics International Restructures and Secures Healius Deal to Drive Diagnostics Push
Jul 27, 2026
Proteomics International Laboratories Ltd has implemented a major organisational restructure to support its shift toward commercial diagnostics, cutting about 25% of positions to save more than $1 million annually and strengthening its cash positi...
Proteomics International Stresses Caution in Investor Presentation
Jul 22, 2026
Proteomics International Laboratories has issued a presentation outlining its disciplined path to commercial success and clarifying the nature of the information provided to investors. The document emphasises that the material is not an offer to s...
Proteomics International Secures Healius Deal for National Promarker Test Rollout
Jul 21, 2026
Proteomics International Laboratories has signed a national Australian distribution agreement with Healius Limited, appointing Healius as the exclusive pathology distribution partner for the Promarker® portfolio for an initial three-year term...
Proteomics International Seeks ASX Quotation for Additional Shares
Jul 12, 2026
Proteomics International Laboratories has applied to the ASX for quotation of 175,604 new ordinary fully paid shares, following the exercise of options or conversion of other securities. The newly issued shares, dated July 13, 2026, will expand th...
Proteomics International wins U.S. patent for non-invasive endometriosis test
Jul 8, 2026
Proteomics International Laboratories, a Perth-based precision diagnostics specialist, is advancing non-invasive, protein-based blood tests through its Promarker platform to address major unmet needs in disease detection. Its PromarkerEndo test fo...
Proteomics International Flags Lapse of Employee Performance Rights
Jul 6, 2026
Proteomics International Laboratories Ltd has notified the market of a change in its issued capital, following the lapse of a tranche of employee performance rights. The company reported that 189,430 PIQAY employee performance rights have ceased, ...
Proteomics International Says No Undisclosed News Behind Share Price Moves
Jul 3, 2026
Proteomics International Laboratories has responded to a query from the ASX regarding recent volatility and increased trading in its shares, stating it is not aware of any undisclosed information that could explain the price movement. The company ...
Proteomics International relocates registered office to Harry Perkins Institute
Jul 2, 2026
Proteomics International Laboratories Ltd, a Perth-based medical technology firm specialising in proteomics and precision diagnostics, operates under the PILL Group and provides bio-analytical services to support improved disease treatment outcome...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.